Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Sep
17
Today In Oncology
FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer
High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC
Zipalertinib Added to Chemotherapy Improves PFS in First-Line EGFR Exon 20 NSCLC
FDA Approves New Labeling of ROS1 Inhibitor for NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo